Eligo Bioscience
Main focus: Treatment of bacterial infections
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-Cas
Funding stage: Private
Location: Paris, France
Website: https://eligo.bio/
Gene editing partnerships: GlaxoSmithKline
Eligo Biosciences seeks to perform precision editing of the human microbiome in order to treat infectious diseases. The company develops engineered phages that deliver CRISPR-Cas systems to pathogenic bacteria. The company has not yet disclosed its lead development programmes, but announced a research and option agreement with GlaxoSmithKline to advance new development candidates from its technology platform.